[Pharmacological profile and clinical efficacy of brimonidine tartrate (AIPHAGAN(®) ophthalmic solution 0.1%)].
e-kaneko@senju.co.jp
Emi
E
Kaneko
Tomoyuki
T
Wada
Yoko
Y
Minagawa
Yutaka
Y
Inoue
D058647:Adrenergic alpha-2 Receptor Agonists / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D000068438:Brimonidine Tartrate; D002986:Clinical Trials as Topic; D005901:Glaucoma / Q000188:drug therapy; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D009883:Ophthalmic Solutions; D011810:Quinoxalines / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*
D058647:Adrenergic alpha-2 Receptor Agonists; D009883:Ophthalmic Solutions; D011810:Quinoxalines; D000068438:Brimonidine Tartrate